New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The company is in the process of appointing the new Chief Financial Officer shortly and in the interim, Komal Gupta will continue as CFO
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company is excited about the strategic progress that the company has made so far and are confident of delivering better business outcomes
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
The company increases its efficiency and is able to face the growing demand for its services.
Subscribe To Our Newsletter & Stay Updated
